Figure 2.

Erythropoietin doses in patients suffering from malignancies or myeloma vs. non-neoplastic patients. Patients who developed malignancies or myeloma during the observation period were excluded. CI: Confidence Interval. Patients with Malignancies/myeloma n. 44: Mean Erythropoietin (IU/Kg/wk): 206.75 (CI 95%, 174.70: 238.79). Patients without Malignancies/myeloma n. 413: Mean Erythropoietin (IU/Kg/Wk): 136.66 (CI 95%, 126.20: 147.12). P < 0.0001. The averages and medians of Erythropoietin doses seem consistently higher in the group of patients with cancer or myeloma but the difference evaluated by the non-parametric method was not statistically significant.

Soffritti et al. BMC Nephrology 2009 10:33   doi:10.1186/1471-2369-10-33
Download authors' original image